АМАбай Каиргожинович Макишев

Абай Каиргожинович Макишев

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Абай Каиргожинович Макишев has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    FLUORESCENCE IMAGING CAPABILITIES IN SECONDARY LYMPHEDEMA FOLLOWING COMPREHENSIVE TREATMENT OF MALIGNANT NEOPLASMS: A CASE SERIES

    by Y.B. Gazizova, U.Y. Kairov, D.A. Begimbetova, A.K. Makishev, A.M. Kukanova

    Background. Secondary upper limb lymphedema is a complication of multimodal treatment for malignant neoplasms associated with damage to the regional lymphatic system. Indocyanine green (ICG) fluorescence lymphography enables real-time visualization of superficial lymphatic vessels and assessment of lymphatic drainage patterns. However, data on fluorescence patterns in secondary lymphedema of different oncological etiologies and their clinical significance remain limited. Objective. To evaluate the diagnostic potential of ICG fluorescence lymphography for detecting and characterizing lymphatic drainage abnormalities in female patients with secondary upper limb lymphedema following multimodal treatment for malignant neoplasms. Materials and Methods. A case series of 10 female patients with secondary upper limb lymphedema following treatment for breast cancer (n = 7), melanoma (n = 2), and cutaneous squamous cell carcinoma (n = 1) was analyzed. The duration of lymphedema before examination ranged from 3 months to 2–3 years. All patients underwent ICG fluorescence lymphography. Results. Fluorescence lymphography revealed four lymphatic drainage patterns: a linear pattern and three types of dermal backflow, namely splash, stardust, and diffuse patterns. The characteristics and extent of fluorescence abnormalities reflected the underlying alterations in lymphatic drainage. Visualization of preserved lymphatic collectors enabled identification of their anatomical location and potential sites for lymphovenous anastomosis. Conclusion. ICG fluorescence lymphography enabled characterization of lymphatic drainage abnormalities and visualization of preserved superficial lymphatic collectors. The findings demonstrated the potential utility of this technique for assessing lymphatic dysfunction, individualizing treatment strategies, and facilitating preoperative planning of lymphovenous anastomosis.

  • Open Access

    CLINICAL EFFICACY AND SAFETY OF VANDETANIB IN METASTATIC MEDULLARY THYROID CARCINOMA: A CASE REPORT

    by A.R. Zhanymbetova, D.A. Begimbetova, A.K. Kukanova, U.Y. Kairov, A.T. Bakisheva, A.K. Makishev

    Background: Medullary thyroid carcinoma is a rare neuroendocrine malignancy characterized by variable clinical behavior, a risk of regional and distant metastasis, and limited systemic treatment options in advanced disease. Vandetanib is one of the therapeutic options for progressive unresectable locally advanced and metastatic medullary thyroid carcinoma; however, published evidence on its use in real-world clinical practice in Kazakhstan remains limited. Objective: To describe the use of vandetanib in a patient with metastatic medullary thyroid carcinoma in real-world clinical practice in Kazakhstan and to analyze the long-term disease course, treatment monitoring, and multidisciplinary management. Materials and methods: A retrospective analysis of a clinical case of a patient with medullary thyroid carcinoma was performed based on medical history, hospital discharge summaries, surgical treatment records, laboratory findings, computed tomography data, and clinical documentation collected over more than six years of follow-up. Tumor progression, distant metastatic spread, functional status, comorbidities, and features of monitoring during vandetanib therapy were assessed. Results: The patient was diagnosed with medullary thyroid carcinoma and underwent surgical treatment. During long-term follow-up, disease progression with metastatic spread involving the lungs, intrathoracic structures, and bone tissue was documented. At the stage of disseminated disease, targeted therapy with vandetanib was initiated. Patient management required regular laboratory, imaging, and cardiac monitoring because of significant comorbidity, the risk of adverse events, and the need for safety surveillance during treatment. Conclusion: This clinical case demonstrates the feasibility of using vandetanib in a patient with metastatic medullary thyroid carcinoma in real-world clinical practice in Kazakhstan. Treatment with vandetanib requires a personalized approach, careful patient selection, multidisciplinary support, and regular safety monitoring, particularly in patients with cardiovascular and metabolic comorbidities. Reporting such cases is important for expanding national experience with targeted therapy in rare thyroid malignancies.

  • Open Access

    EXPLORING THE INTRAVENOUS COMBINATION OF D-ISOASCORBIC ACID (D-VC) AND ARSENIC TRIOXIDE IN ADVANCED/METASTATIC MALIGNANCIES

    by B.A. Yermekbayeva, U.Y. Kairov, D.A. Begimbetova, A.M. Kukanova, A.K. Makishev

    Background: Addressing the therapeutic challenges associated with Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) mutant cancers remains a significant focus in oncology. The combined intravenous administration of the D-isomer of vitamin C (D-VC) (dextro-rotatory isomer of ascorbic acid) and arsenic trioxide (ATO) is proposed as a potential approach for achieving an anti-tumor effect in Colorectal cancer (CRC) with KRAS-mutant tumor cells. ATO enhances the oxidative effect of vitamin C (VC), and the combination of both drugs provides effective eradication of KRAS-mutant cancer cells. A potent synergistic effect of the VC and ATO combination has been observed about KRAS-mutant cancer cells. Purpose: This clinical trial aims to assess the tolerability and safety of intravenous administration of D-VC along with ATO in patients with advanced/metastatic malignancies who have exhausted standard therapy. Methods and Patients: This single-center Phase I clinical trial evaluated the tolerability and safety of D-VC when administered intravenously alone or in sequential administration with ATO. The target group for the Phase I exploratory clinical trial includes 10 patients with advanced/metastatic malignant neoplasms who have exhausted standard therapy. Results: The administration of the drug followed the treatment regimen according to the ap-proved study protocol. After a single intravenous infusion of D-VC in escalating doses of 0.05 g/kg - 0.1 g/kg - 0.15 g/kg - 0.3 g/kg all patients felt satisfactory, and no subjective intolerance to the investigational drug was reported. The main functional and laboratory parameters remained within normal values recorded at the start of the study. The maximum tolerated dose of D-VC was determined to be 0.3 g/kg, and this dose was chosen as the baseline for the second stage of the study, where D-VC (0.3 g/kg) was administered alongside ATO (0.15 mg/kg). Conclusions: Our findings showed favorable safety and well-tolerated profiles and provided the recommended dose for high-dose D-VC in combination with АТО.

  • Open Access

    Динамика болевого синдрома у пациенток с метастатическим поражением позвоночника при раке молочной железы после стандартного и расширенного мультимодального лечения: Результаты проспективного когортного исследования

    by А.а. Айтбаева, А.т. Бекишева, А.к. Макишев, Д.а. Бегимбетова, У.е. Каиров, А.е. Гуляев

    Метастатическое поражение позвоночника является одним из наиболее тяжелых осложнений распространенного рака молочной железы и сопровождается выраженным хроническим болевым синдромом, снижением функциональной активности и ухудшением качества жизни пациенток. Современный подход к лечению включает комплексное применение локальных, системных и поддерживающих методов терапии, однако оценка эффективности отдельных компонентов мультимодального лечения остается актуальной задачей. Цель исследования: оценить динамику болевого синдрома у пациенток с метастатическим поражением позвоночника при раке молочной железы после проведения стандартного и расширенного мультимодального лечения. Методы. Проведено проспективное открытое контролируемое нерандомизированное когортное исследование с параллельным сравнением двух групп. В исследование включены 75 пациенток с гистологически подтвержденным раком молочной железы IV стадии и радиологически верифицированными метастазами позвоночника. Все пациентки получали стандартное мультимодальное лечение, включавшее чрескожную вертебропластику, лучевую терапию и антиостеорезорбтивную терапию. В основной группе (n=30) дополнительно применялась нутритивная поддержка сублимированным кобыльим молоком - саумал, в контрольной группе (n=45) дополнительная нутритивная поддержка не применялась. Интенсивность болевого синдрома оценивали по визуально-аналоговой шкале (ВАШ) до лечения, через 2 недели, 1, 3 и 6 месяцев после начала терапии. Результаты. Исходный уровень болевого синдрома был сопоставим между группами: показатель ВАШ составил 7,37±0,56 балла в основной группе и 7,40±0,62 балла в контрольной группе (p=0,927). В процессе наблюдения в обеих группах отмечено статистически значимое снижение интенсивности боли относительно исходного уровня (p<0,001). Через 6 месяцев показатель ВАШ составил 3,23 ± 0,73 балла в основной группе и 3,16 ± 0,64 балла в контрольной группе. Различий между группами по динамике болевого синдрома выявлено не было (p=0,761). Снижение интенсивности боли более чем на 2 балла достигалось уже через 2 недели после начала лечения и сохранялось на протяжении всего периода наблюдения. Выводы. Стандартное мультимодальное лечение пациенток с метастатическим поражением позвоночника при раке молочной железы обеспечивает выраженное и устойчивое снижение болевого синдрома в течение шестимесячного периода наблюдения. Дополнительное включение саумал в лечебный комплекс не продемонстрировало статистически значимого преимущества по показателям ВАШ, однако не изменяло положительный эффект базового мультимодального подхода.

  • Open Access

    QUALITY OF LIFE OUTCOMES FOLLOWING ULTRASONIC DISSECTOR-ASSISTED VS. ELECTROCAUTERY DISSECTION IN MODIFIED RADICAL MASTECTOMY: PROSPECTIVE OBSERVATIONAL COHORT

    by Nazgul Dzhantemirova, Marat Mauletbaev, Asiya Kukanova, Aizhan Bekisheva, Abay Makishev

    Background: Breast cancer is one of the most common malignancies worldwide, with significant implications for patient quality of life (QoL). As survival rates improve, assessing the long-term effects of treatment has become crucial. Conventional electrocautery has been widely used for axillary lymph node dissection (ALND), but recent studies suggest that ultrasonic dissectors (ULDs) may offer advantages by reducing tissue trauma and postoperative complications. This study evaluates the impact of ALND using ULDs versus electrocautery on QoL in breast cancer patients. Methods: An observational study was conducted involving 73 female breast cancer patients (aged 18–80 years) undergoing modified radical mastectomy with ALND. Patients were divided into two groups: an intervention cohort (n=35) treated with the Söring Sonoca 300 ultrasonic dissector and a control cohort (n=38) treated with conventional electrocautery. QoL was assessed using the EORTC QLQ-C30 and QLQ-BR45 questionnaires at baseline, 3-, 6-, and 9-months post-treatment. Statistical analysis included chi-square tests for categorical variables and independent t-tests for continuous variables, with p<0.05 significancy. Results: At baseline, no significant differences were observed between the groups. However, at three months, the intervention group demonstrated significantly higher functional scores (66.3±8.2 vs. 59.0±6.7; p<0.001), lower symptom scores (41.7±4.0 vs. 46.3±5.6; p<0.001), and superior global health status (64.2±9.9 vs. 51.4±10.8; p<0.001). These improvements persisted at six months, with the intervention group maintaining better functional scores (76.2±10.2 vs. 57.5±7.3; p<0.001), lower symptom scores (37.9±7.8 vs. 44.9±9.6; p<0.001), and higher global health status (66.5±10.4 vs. 52.6±13.1; p<0.001). By nine months, the intervention group continued to exhibit superior outcomes: functional scale (79.5±11.1 vs. 64.8±9.9; p<0.001), symptom scale (38.3±7.8 vs. 45.4±7.0; p<0.001), and global health status (71.5±6.6 vs. 56.3±8.2; p<0.001). Conclusion: Reduced thermal damage and improved healing contribute to better functional outcomes and lower symptom burden. These findings support the integration of ULDs into surgical oncology practice to optimize patient recovery.

  • EVALUATION OF ULTRASONIC DISSECTION TECHNOLOGY IN REDUCING POST-MASTECTOMY SYNDROME RATES: A COMPARATIVE STUDY WITH CONVENTIONAL ELECTROCAUTERY IN AXILLARY LYMPH NODE DISSECTION

    by N Dzhantemirova, M Mauletbaev, D Akhmedin, A Bekisheva, Astana Multidisciplinary Medical Center Of Astana, A Makishev

    Annotation Background. Post-mastectomy syndrome, characterized by chronic pain, lymphedema, and functional impairment, remains a significant complication following breast cancer surgery. This study evaluates the efficacy of ultrasonic dissection technology in reducing morbidity associated with post-mastectomy syndrome compared with conventional electrocautery during axillary lymph node dissection. Methods. A prospective study enrolled 53 female patients (aged 29–81 years) undergoing Madden technique mastectomy, stratified into ultrasonic dissection technology (n=25) and electrocautery (n=28) groups. Primary outcomes included operative duration, intraoperative blood loss, drainage metrics, and 30-day complication rates. Both groups exhibited comparable demographics, with high body mass index prevalence (64% overweight/obese) but balanced intergroup distribution. Results. Ultrasonic dissection technology’s cavitational mechanism preserved neurovascular and lymphatic structures, potentially mitigating long-term lymphedema risks. Despite equivalent short-term complication rates, ultrasonic dissection technology enhanced operative efficiency without compromising safety. The ultrasonic dissection technology cohort demonstrated a statistically significant reduction in operative time, p<0.001, attributed to streamlined hemostasis and reduced instrument swaps. Significant differences were observed in drainage volume, blood loss anddrainage duration (p<0.001), overall postoperative complications. Conclusions. Ultrasonic dissection technology represents a promising advancement in oncologic surgery, offering faster procedures and economic advantages while maintaining safety. This study underscores ultrasonic dissection technology’s potential to refine surgical precision and improve postoperative recovery trajectories in breast cancer care.

  • SURGICAL METHODS OF PREVENTION OF POST-MASTECTOMY SYNDROME: A LITERATURE REVIEW

    by N. Dzhantemirova, M. Mauletbayev, A. Bekisheva, A. Kukanova, D. Akhmedin, A. Makishev

    Relevance: Despite improvements in early diagnosis, breast cancer continues to be one of the most common types of malignant tumors in the Republic of Kazakhstan, affecting about 5,000 women annually. Surgery remains the main method of treatment for breast cancer. Rapid development and improvement of various methods and devices for reconstructive plastic surgery plays an important role in the medical, psychological, and social rehabilitation of patients with breast cancer, allowing to achieve better aesthetic and functional results. Postmastectomy syndrome (PMPS) is a complex complication of surgical tumor resection and affects almost half of women who have undergone this intervention. The study aimed to analyze surgical methods for the prevention of postmastectomy syndrome to improve the outcomes, the course of the postoperative period and the quality of life of patients. Methods: Data from MEDLINE, Embase, Scopus, PubMed, and Cochrane Central Register of Controlled Trials were analyzed to select and analyze relevant information over the past 10 years using the keywords: “postmastectomy syndrome,” “mastectomy,” “lymphedema,” “brachioplexitis.” Results: The literature analysis showed that treating PMS requires a comprehensive approach, since the manifestations of PMS may vary depending on individual characteristics, the extent of surgical intervention, and other individual factors. The effectiveness of the interventions varied, with some showing promising results in reducing pain intensity, while others demonstrated improvements in functional outcomes and quality of life. Thus, it was found that ultrasound dissection is superior to electrocoagulation in terms of intraoperative blood loss, amount of lymphorrhea, and average hospital stay. Lymphatic-venous anastomoses are difficult to reproduce, but have been reported to be 95% effective in preventing lymphedema. Autologous fat tissue transplantation solves several problems, including reducing chronic pain syndrome (>6 months) by 3.1 points. Brachioplexitis and associated complications can be prevented during surgery. Conclusions: Given the variability of PMS complications, it is advisable to prevent the burden and financial costs of rehabilitation in the postoperative period. Surgical methods of prevention discussed in this literature review can be used intraoperatively to significantly reduce the risk of PMS.

  • Open Access

    КЛИНИЧЕСКИЙ СЛУЧАЙ ТЕРАПИИ НЕМЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКОГО С ЭКСПРЕССИЕЙ PD-L1

    by Туменбаева Ж.с., Макишев А.к.

    Иммунотерапия методом выбора персонифицированного лечения с учетом эффективности, благоприятного профиля токсичности и переносимости, согласующихся с результатами рандомизированных клинических исследований (KEYNOTE) - это новый перспективный подход к лечению метастатического немелкоклеточного рака легкого. В настоящее время в лечении немелкоклеточного рака легкого значительно расширился спектр иммунотерапевтических препаратов, применение которых позволяет добиться контроля над опухолью с сохранением качества жизни пациентов и снижение, либо отсутствие клинических симптомов и иммуноопосредованных нежелательных явлений. Один из таких препаратов – Пембролизумаб (моноклональное антитело, блокирующее взаимодействие между PD-1 и его лигандами (PD-L1/PD-L2)), который применяется как во второй, так и в первой линии терапии, при условии высокого уровня экспрессии PD-L1 (≥50%). В данной работе представлено описание клинического случая пациента с немелкоклеточным раком легкого, с экспрессией PD-L1, получавшего иммунотерапию препаратом пембролизумаб. В процессе иммунотерапии в динамике у пациента клинически уменьшились кашель, боли в грудной клетке, улучшилось качество жизни и длительность частичной регрессии на более чем 6 месяцев. На протяжении всего периода лечения и наблюдения иммуноопосредованных нежелательных явлений у пациента не отмечалось. Данные, представленные в статье, будут полезны онкологам, химиотерапевтам, онкохирургам, радиологам, гистологам, терапевтам. Immunotherapy by choosing a personalized treatment based on efficacy, favorable toxicity profile and tolerability consistent with the results of randomized clinical trials (KEYNOTE) is a promising new approach to the treatment of metastatic non-small cell lung cancer. Currently, in the treatment of non-small cell lung cancer, the range of immunotherapeutic drugs has significantly expanded, the use of which makes it possible to achieve tumor control while maintaining the quality of life of patients and reducing or absence of clinical symptoms and immuno-mediated adverse events. One of these drugs is Pembrolizumab (a monoclonal antibody that blocks the interaction between PD–1 and its ligands (PD-L1/PD-L2)), which is used in both second and first-line therapy, provided a high level of PD-L1 expression (≥50%). This paper describes a clinical case of a patient with non-small cell lung cancer, with PD-L1 expression, who received immunotherapy with pembrolizumab. During immunotherapy, the patient's cough and chest pain decreased clinically, the quality of life and the duration of partial regression improved by more than 6 months. There were no immuno-mediated adverse events in the patient during the entire period of treatment and follow-up. The data presented in the article will be useful to oncologists, chemotherapists, oncosurgeons, radiologists, histologists, therapists. Рандомизацияланған клиникалықзерттеулердің(KEYNOTE) нәтижелеріне сәйкес тиімділікті, жағымсыз жанама әсерлердің аз болуы мен төзімділіктің қолайлы белгілерін ескере отырып, жекелендірілген емдеуді таңдау арқылы иммунотерапия метастаздық ұсақ жасушалы емес өкпе обырын емдеудің жаңа перспективалық тәсілі болып табылады. Қазіргі уақытта ұсақ жасушалы өкпе обырын емдеуде иммунотерапиялықпрепараттардың спектрі едәуір кеңейді, оларды қолдану науқастардың өмір сүру сапасын сақтай отырып, ісікті бақылауға қол жеткізуге және клиникалықбелгілердің азаюына, иммундық жағымсыз әсерлердің төмендеуіне мүмкіндік береді. Осындай препараттардыңбірі-Пембролизумаб (PD-1 мен оның лигандтары (PD-L1/PD-L2) арасындағы өзара әрекеттесуді блоктайтын моноклоналды антидене), ол PD-L1 экспрессиясының жоғары деңгейі (≥50%) жағдайында терапияның екінші және бірінші желісінде қолданылады. Бұл жұмыста иммунотерапияның пембролизумаб препаратын қабылдаған PD-L1 экспрессиясы бар ұсақ жасушалы емес өкпе обырындағы науқастыңклиникалық...

  • Open Access

    Clinical, epidemiological and genetic features of colorectal cancer

    by A. M. Kukanova, A. T. Bekisheva, A. K. Makishev

    Introduction. The incidence of colorectal cancer for 2020 was 1931590 cases, which is 10 % of all new cases of incidence, and mortality from colorectal cancer ranks 2nd among cancer deaths, it is 935 173 cases (9.4 %) according to Globocan 2020. According to statistics of the Kazakh Research Institute of Oncology and Radiology for 2019–2020 сolorectal cancer ranks 3rd in the structure of oncopathology, both in terms of morbidity and mortality. The occurrence of colorectal cancer is associated with an interaction that occurs at several levels between hereditary, environmental and individual factors. Understanding the molecular basis is important because it can identify factors that initiate development, maintain progression, and determine response or resistance to anticancer agents.Aim. To describe the main genetic mutations and their impact on treatment prognosis, diagnosis and course of colorectal cancer.Materials and methods. A systematic literature review of scientific databases Cochrane, PubMEd, MedLine, Elsevier was carried out. For the main search, the main search terms are formulated: colorectal cancer, mutations in colorectal cancer, molecular genetic studies in colorectal cancer, mutation of the KRAS gene. Also, a time range was set no later than 5 years, i. e. all articles published from 2017 to the current year.Results. The main molecular changes in colorectal cancer are Chromosome instability, microsatellite instability, and abnormal DNA methylation. Suppressor genes, such as Ras, EGFR (Erb-B1), Erb-B2, TGF-alpha, and TGF-beta 1, are also of great importance.Conclusion. Research that contributes to the understanding of the molecular basis of colorectal cancer helps in the early diagnosis of familial cancer, treatment prognosis and a personalized approach to patient treatment.

  • Open Access

    ОЦЕНКА ЭФФЕКТИВНОСТИ ТАРГЕТНОЙ ТЕРАПИИ РАКА ЛЕГКОГО В ТУРКЕСТАНСКОЙ ОБЛАСТИ ЗА 2019-2022 ГОДЫ

    by Ж.с. Туменбаева, А.к. Макишев

    Введение: Лечение пациентов раком легкого является одной из актуальных проблем современной медицины. Обнаружение мутации гена рецептора эпидермального фактора роста (EGFR-Epidermal Growth Factor Receptor) является важным шагом в лечении широко распространенного немелкоклеточного рака легких. Исследования ученых показывают, что использование препаратов таргетной терапии у пациентов с диссеминированным немелкоклеточным раком легкого и наличием мутации EGFR является клинически эффективным, так как приводит к существенному увеличению частоты объективных эффектов и улучшению выживаемости без прогрессирования, в сравнении с результатами химиотерапии. Цель исследования. Оценка эффективности таргетной терапии рака легкого в Туркестанской области за 2019-2022 годы. Материалы и методы: Проведено ретроспективное статистическое исследование результатов лечения при помощи анализа выживаемости методом Каплана-Мейера и по критериям RECIST. Пациенты были рандомизированы (1:1) с использованием процедуры минимизации и стратифицированы в соответствии с типом мутации EGFR. Первичным результатом была выживаемость без прогрессирования, проанализированная у пациентов с подтвержденным заболеванием, получивших хотя бы несколько доз исследуемого препарата. За исследуемый период в Туркестанской области рассматривались 96 пациентов с заболеванием рак легкого с мутацией EGFR, из них 48 получали таргетную терапию (афатиниб – 28 (58%) пациентов, эрлотиниб – 11 (58%), пациентов, осимертиниб – 9 (58%) пациентов), а остальные 48 получали химиотерапию. В качестве анализируемых показателей рассматривались: возраст пациента, пол, гистологические данные, диагноз, стадии, виды лечения. Все статистические расчеты проводились с использованием программы SPSS (версия 25.0, IBM SPSS Inc., Чикаго, США). Данные были обобщены с использованием методов описательной статистики. Результаты: медиана выживаемости без прогрессирования при приеме афатаниба составляет 12,6 месяцев, при химиотерапии – 5,8 месяцев. У пациентов, принимающих препарат афатиниб, прогрессирование наблюдается в 0,266667 раза реже, чем у пациентов, получавших химиотерапию, т.к. доверительный интервал не содержит 1, то связь между приемом афатиниба и временем наступления прогрессирования является статистически значимой (p<0,05). То есть, медиана выживаемости без прогрессирования была значительно выше у пациентов, получавших афатиниб, чем у пациентов, получавших химиотерапию (12,6 против 5,8 месяцев; ОР=0,26667, 95% ДИ 0,10088–0.703733; p< 0,05). Медиана выживаемости без прогрессирования при приеме эрлотиниба составляет 13,8 месяцев, при химиотерапии – 4,8 месяцев. У пациентов, принимавших эрлотиниб, прогрессирование наблюдается в 0,2223 раза реже, чем у пациентов, получавших химиотерапию, то связь между приемом эрлотиниба и временем наступления прогрессирования является статистически значимой (p<0,05). То есть, медиана выживаемости без прогрессирования была значительно выше у пациентов, получавших эрлотиниб, чем у пациентов, получавших химиотерапию (13,8 против 5,8 месяцев; ОР=0,2223, 95% ДИ 0,187457–0.932733; p< 0,05). Медиана выживаемости без прогрессирования при приеме осимертиниба составляет 10 месяцев, при химиотерапии – 4,6 месяцев. У пациентов, принимающих препарат осимертиниб, прогрессирование наблюдается в 0,42857 раза реже, чем у пациентов, получавших химиотерапию,...